Stemsynergy Therapeutic

Address

1951 NW 7th Ave, Ste 300
Miami, FL, 33136-1112

Information

DUNS: 826941754
# of Employees: 3

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis

    Amount: $224,991.00

    DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function m ...

    STTRPhase I2016Department of Health and Human Services
  2. Development of a LRP6 Monoclonal Antibody for Triple Negative Breast Cancer

    Amount: $224,968.00

    DESCRIPTION provided by applicant Triple negative breast cancer TNBC represents an aggressive tumor type with a distinct lack of effective treatment options Standard of care chemotherapy regimen ...

    SBIRPhase I2016Department of Health and Human Services
  3. Development of a WNT Inhibitor for Regenerative Healing of Burn Injuries

    Amount: $225,000.00

    ABSTRACT Burns represent one of the most traumatic and debilitating injuries affecting over million people in the United States Reparative processes occurring after acute burn injury ultimately res ...

    SBIRPhase I2016Department of Health and Human Services
  4. Development of a WNT Inhibitor for Advanced Stage Lung Cancer

    Amount: $1,499,974.00

    DESCRIPTION provided by applicant Non small cell lung cancer NSCLC is the most common lung cancer Half of NSCLC shows WNT activation marking poor survival StemSynergy Therapeutics Inc SSTI h ...

    SBIRPhase II2014Department of Health and Human Services
  5. Development of Wnt Pathway Inhibitors for Colorectal Cancer

    Amount: $1,999,997.00

    DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fun ...

    SBIRPhase II2012Department of Health and Human Services
  6. Targeting stem cell populations in lung cancer by modulating the Wnt and p53 path

    Amount: $259,451.00

    DESCRIPTION (provided by applicant): Despite significant advancements in modern medicine with regards to surgery, radiation therapy and imaging of tumors, the survival rate for patients with non-small ...

    SBIRPhase I2012Department of Health and Human Services
  7. Development of Wnt Pathway Inhibitors for Colorectal Cancer

    Amount: $140,000.00

    DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fund ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government